C4 Therapeutics
NASDAQ: CCCCCambridge, US · Founded 2015 · Delaware corporation · 4 known investors
C4 Therapeutics develops small molecule medicines called degraders that use targeted protein degradation (TPD) to eliminate disease-causing proteins via the body's ubiquitin proteasome system. The company works on investigational therapies aimed at overcoming drug resistance and reaching targets considered undruggable.
Founders & leadership
MC
Marc CohenExecutive Officer, Director
JF
Jason FishermanExecutive Officer, Director
MS
Miles StuchinDirector
WM
William M. ScalzulliDirector
KA
Kenneth AndersonDirector
MS
Malcolm S. SalterDirector
BD
Bruce DowneyDirector
JE
Jay EastmanDirector
AC
Alain CohenDirector
EP
Elena ProkupetsDirector
BC
Bihua ChenDirector
RW
Ronald W. KaiserDirector
Investors · 4
Reported raises · per SEC filings
Form D private placements▶$70.3MraisedJan 2016 · 55 investors · BiotechnologyRule 506(b)
▶$70.3MraisedJan 2016 · 55 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Marc CohenExecutive Officer, Director
- Jason FishermanExecutive Officer, Director
- Miles StuchinDirector
- William M. ScalzulliDirector
- Kenneth AndersonDirector
- Malcolm S. SalterDirector
- Bruce DowneyDirector
- Jay EastmanDirector
- Alain CohenDirector
- Elena ProkupetsDirector
- Bihua ChenDirector
- Ronald W. KaiserDirector
- Offering amount
- $73.5M
- Amount sold
- $70.3M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.